Clarisa R. Gracia, M. D. , M. S. C. E. , Christopher B. Morse, B. A

Slides:



Advertisements
Similar presentations
Clarisa R. Gracia, M. D. , M. S. C. E. , Christopher B. Morse, B. A
Advertisements

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Gestational hypothyroidism: development of mild hypothyroidism in early pregnancy in previously euthyroid women  Karen R. Hammond, D.N.P., C.R.N.P., Nicholas.
Complete septate uterus with longitudinal vaginal septum
Cost-effectiveness of presumptively medically treating women at risk for ectopic pregnancy compared with first performing a dilatation and curettage 
Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates  Liang Zhou, M.D., Rong Li, M.D., Ph.D., Rong.
Fertility and Sterility  Volume 97, Issue 3, Pages (March 2012)
Fernando Zegers-Hochschild, M.D.  Fertility and Sterility 
Michael M. Alper, M.D.  Fertility and Sterility 
Performance of human chorionic gonadotropin curves in women at risk for ectopic pregnancy: exceptions to the rules  Christopher B. Morse, B.A., Mary D.
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.
Ovarian pregnancy after in vitro fertilization
Growth rates of ovarian follicles during natural menstrual cycles, oral contraception cycles, and ovarian stimulation cycles  Angela R. Baerwald, Ph.D.,
Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D
Isabel Cerveira, M. D. , Cristina Costa, M. D. , Fernando Santos, M. D
Comparison of fallopian tube sperm perfusion and intrauterine tuboperitoneal insemination: a prospective randomized study  Leonidas Mamas, M.D., Ph.D. 
Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women  Ellen W. Freeman, Ph.D.,
Medical treatment of ectopic pregnancy: a committee opinion
Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain  David S. Guzick, M.D.,
Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers  Andrea.
Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D. 
How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization  Robert L. Klitzman, M.D.  Fertility.
Application of redefined human chorionic gonadotropin curves for the diagnosis of women at risk for ectopic pregnancy  Beata E. Seeber, M.D., Mary D.
Ellen W. Freeman, Ph. D. , Clarisa R. Gracia, M. D. , Mary D
A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data 
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Prospective evaluation of luteal phase length and natural fertility
Oocyte cryopreservation
Two interesting cases of ovarian pregnancy after in vitro fertilization–embryo transfer and its successful laparoscopic management  Selvaraj Priya, M.D.,
How and when human chorionic gonadotropin curves in women with an ectopic pregnancy mimic other outcomes: differences by race and ethnicity  Katherine.
Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review  Seema Menon, M.D., John.
Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis  Cui Hong Zheng, M.D., Ph.D.,
Robert F. Casper, M.D.  Fertility and Sterility 
Association of the very early rise of human chorionic gonadotropin with adverse outcomes in singleton pregnancies after in vitro fertilization  Christopher.
A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization  Laura Detti, M.D., Daniel B. Williams, M.D., Jared.
Katherine D. LaGuardia, M. D. , M. P. H. , Alan C. Fisher, Dr. P. H
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Epidemiology of male and female reproductive disorders and impact on fertility regulation and population growth  Kurt T. Barnhart, M.D., M.S.C.E.  Fertility.
Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis  Laura P. Smith, M.D.,
Maternal complication of cervical heterotopic pregnancy after successful potassium chloride fetal reduction  Cynthia Gyamfi, M.D., Samantha Cohen, B.A.,
Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles  Karin.
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Use of “2-dose” regimen of methotrexate to treat ectopic pregnancy
Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro.
Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception  Lauren N.C. Johnson,
Thomas M. D’Hooghe, M. D. , Ph. D. , Bénédicte Denys, M. D
“Information-rich” reproductive outcomes in carriers of a structural chromosome rearrangement ascertained on the basis of recurrent pregnancy loss  Michelle.
A longitudinal study of the effects of free testosterone and other psychosocial variables on sexual function during the natural traverse of menopause 
Aviad Cohen, M. D. , Guy Bibi, M. D. , Benny Almog, M. D
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
Website quality assessment: Mistaking apples for oranges
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization  David W. Schmidt, M.D.,,
Fertility and Sterility: an evaluation
Chantae Sullivan-Pyke, M. D. , Daniel J. Haisenleder, Ph. D
Sedigheh Borna, M.D., Azita Nasery, M.D.  Fertility and Sterility 
Impact of subclinical hypothyroidism in women with recurrent early pregnancy loss  Lia A. Bernardi, M.D., Ronald N. Cohen, M.D., Mary D. Stephenson, M.D.,
Female cancer survivors exposed to alkylating-agent chemotherapy have unique reproductive hormone profiles  Lauren Johnson, M.D., M.S.C.E., Mary D. Sammel,
The J-Tip Needle-Free Injection System in controlled ovarian hyperstimulation in in vitro fertilization: a pilot study  Stuart A. Lavery, M.R.C.O.G.,
Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories  Melissa C. Yih, M.D.,
In vitro sildenafil citrate use as a sperm motility stimulant
Which patients pursue fertility preservation treatments
Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy  Eman A. Elgindy,
Briana J. Rudick, M. D. , Sue Ann Ingles, Ph. D. , Karine Chung, M. D
Thyroid function after controlled ovarian hyperstimulation in women with and without the hyperstimulation syndrome  Kris Poppe, M.D., Ph.D., David Unuane,
Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:
Is chromosome testing of the second miscarriage cost saving
Hyperglycosylated human chorionic gonadotropin as an early predictor of pregnancy outcomes after in vitro fertilization  Sandy Chuan, M.D., Michael Homer,
Presentation transcript:

Thyroid function during controlled ovarian hyperstimulation as part of in vitro fertilization  Clarisa R. Gracia, M.D., M.S.C.E., Christopher B. Morse, B.A., Grace Chan, M.D., Samantha Schilling, M.D., Maureen Prewitt, R.N., Mary D. Sammel, Sc.D., Susan J. Mandel, M.D., M.P.H.  Fertility and Sterility  Volume 97, Issue 3, Pages 585-591 (March 2012) DOI: 10.1016/j.fertnstert.2011.12.023 Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions

Figure 1 (Top) TSH over time by hypothyroid status. (Bottom) Free T4 over time by hypothyroid status. Geometric mean values with standard error bars shown. For both: euthyroid–TPOAb negative (n = 45) and hypothyroid-treated (n = 9). ∗P≤.01 for within-group comparisons at each time point compared with time 1. †P≤.01 for between-group comparisons at each time point. Time points: 1) before stimulation; 2) 4–7 days after initiating stimulation; 3) at hCG administration; 4) 1 week after hCG; 5) at pregnancy test; and 6) 2 weeks after pregnancy test. Fertility and Sterility 2012 97, 585-591DOI: (10.1016/j.fertnstert.2011.12.023) Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions

Figure 2 (Top) Estradiol over time by hypothyroid status. (Bottom) TBG over time by hypothyroid status. Geometric mean values with standard error bars shown. For both: euthyroid-TPOAb negative (n = 45) and hypothyroid-treated (n = 9). ∗P≤.01 for within-group comparisons at each time point compared with time 1. †P≤.01 for between-group comparisons at each time point. Time points: 1) before stimulation; 2) 4–7 days after initiating stimulation; 3) at hCG administration; 4) 1 week after hCG; 5) at pregnancy test; and 6) 2 weeks after pregnancy test. Fertility and Sterility 2012 97, 585-591DOI: (10.1016/j.fertnstert.2011.12.023) Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions

Figure 3 (Top) TSH over time by pregnancy (pregnant [n = 19] vs. not pregnant [n = 38]). ∗P≤.01 for within-group comparisons at each time point compared with time 1. †P≤.01 for between-group comparisons at each time period. (Bottom) TSH over time in participants that became pregnant (16 euthyroid–TPOAb-negative participants and two hypothyroid participants). Both hypothyroid participants had an increase in LT4 dose between times 5 and 6 (#). Geometric mean values with standard error bars shown. Time points: 1) before stimulation; 2) 4–7 days after initiating stimulation; 3) at hCG administration; 4) 1 week after hCG; 5) at pregnancy test; and 6) 2 weeks after pregnancy test. Fertility and Sterility 2012 97, 585-591DOI: (10.1016/j.fertnstert.2011.12.023) Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions